Foxconn third-quarter revenue jumps 20% yr/yr-March 2024-www.financetom.com

Foxconn third-quarter revenue jumps 20% yr/yr

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Foxconn third-quarter revenue jumps 20% yr/yr

Oct 5, 2024 1:14 AM

TAIPEI, Oct 5 (Reuters) - Taiwan's Foxconn,

the world's largest contract electronics maker and Apple's ( AAPL )

biggest iPhone assembler, reported on Saturday that its

third-quarter revenue jumped 20.2% year on year.

"The result exceeded the company's original expectations of

significant growth," Foxconn said in a statement.

Previous page： Pfizer Says Lorbrena Shows Positive Long-Term Results in Advanced Lung Cancer Patients Next page： International Motor Show to no longer be held in Geneva, organisers say

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Pfizer Says Lorbrena Shows Positive Long-Term Results in Advanced Lung Cancer Patients

May 31, 2024

09:13 AM EDT, 05/31/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that longer-term follow-up results from the phase 3 CROWN trial showed benefits of Lorbrena over Xalkori for previously untreated, anaplastic lymphoma kinase-positive advanced non-small cell lung cancer patients. After five years of median follow-up, Lorbrena demonstrated an 81% reduction in disease progression or death compared to Xalkori,...

International Motor Show to no longer be held in Geneva, organisers say

May 31, 2024

PARIS (Reuters) - Organisers of the annual Geneva Motor Show said on Friday they will no longer hold the event in Geneva, citing an uncertain market environment. They added in a statement that they were still planning to hold the Qatar edition of the show in November. ...

Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy

May 31, 2024

09:20 AM EDT, 05/31/2024 (MT Newswires) -- Novartis AG ( NVS ) said Friday that pivotal phase 3 data showed the long-term efficacy and safety of its investigational drug remibrutinib to treat chronic spontaneous urticaria. The company said treatment with remibrutinib showed significant symptom improvement that was sustained up to 52 weeks in patients who continued to manifest symptoms despite...

Billionaire investor Ackman plans IPO of Pershing Square, WSJ reports

May 31, 2024

May 31 (Reuters) - Hedge fund billionaire Bill Ackman is planning an initial public offering for his investment firm Pershing Square Capital Management as soon as next year, the Wall Street Journal reported on Friday, citing people familiar with the matter. A booming stock market and economic resilience have spurred a spate of companies to list their shares and take...